NASDAQ:VRML

Vermillion (VRML) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.81
$3.16
50-Day Range
$2.54
$4.24
52-Week Range
$0.35
$5.78
Volume
23,072 shs
Average Volume
440,144 shs
Market Capitalization
$289.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VRML stock logo

About Vermillion Stock (NASDAQ:VRML)

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

VRML Stock News Headlines

Camellia Vermillion
Dr. Richard L. Knutson
The 2024 Gold Rush: Unleashing Market Potential
Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.
Vermillion Elementary School
Dr. Kenneth J. Vermillion
Vermillion High School
Sanford Vermillion Medical Center
The 2024 Gold Rush: Unleashing Market Potential
Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.
Wednesday's Local Sports Scores - Yahoo News
Local Sports Calendar (Sept. 13) - Yahoo News
See More Headlines
Receive VRML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vermillion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2019
Today
5/11/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:VRML
Fax
N/A
Employees
43
Year Founded
N/A

Profitability

Net Income
$-15,240,000.00
Net Margins
-307.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.54 million
Book Value
$0.09 per share

Miscellaneous

Free Float
N/A
Market Cap
$298.95 million
Optionable
Not Optionable
Beta
3.47
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Ms. Valerie Barber Palmieri (Age 58)
    CEO, Pres & Director
  • Mr. Robert Harry Beechey CPA (Age 56)
    Chief Financial Officer
  • Mr. Chris Goulart
    Sr. VP of Commercial Operations

VRML Stock Analysis - Frequently Asked Questions

How were Vermillion's earnings last quarter?

Vermillion, Inc. (NASDAQ:VRML) issued its earnings results on Thursday, August, 8th. The company reported ($0.06) EPS for the quarter. The firm earned $1.14 million during the quarter. Vermillion had a negative net margin of 307.31% and a negative trailing twelve-month return on equity of 155.25%.

What other stocks do shareholders of Vermillion own?
This page (NASDAQ:VRML) was last updated on 5/11/2024 by MarketBeat.com Staff

From Our Partners